Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Study Investigating a New, Oral Growth Hormone Secretagogue (GHS)(AEZS 130, Formerly ARD-07) as a Growth Hormone (GH) Stimulation Test in Terms of Safety and Efficacy

Next Previous
Trial Profile

A Multi-center, Study Investigating a New, Oral Growth Hormone Secretagogue (GHS)(AEZS 130, Formerly ARD-07) as a Growth Hormone (GH) Stimulation Test in Terms of Safety and Efficacy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Macimorelin (Primary)
  • Indications Growth disorders
  • Focus Diagnostic use; Registrational
  • Sponsors AEterna Zentaris Inc; Ardana plc

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Nov 2013 New trial record
    • 05 Nov 2013 Data from this trial have been included in an NDA submitted to the FDA for the use of macimorelin in the diagnosis of adult growth hormone deficiency, according to an Aeterna Zentaris media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top